2024 Election Year Stocks: Uncover Hidden Gems!

In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.

Secure your copy now by clicking this link.

R. Michael Carruthers net worth and biography

R. Michael Carruthers Biography and Net Worth

CFO of Edgewise Therapeutics

Michael Carruthers has served as our Chief Financial Officer since September 2020. Mr. Carruthers has over 20 years of experience serving as Chief Financial Officer for publicly-traded biopharmaceutical companies, with extensive experience across corporate finance and strategic planning including IPOs, secondary offerings and M&A transactions. Most recently, Mr. Carruthers consulted as Chief Financial Officer for several private and public companies. Previously, Mr. Carruthers served as Interim President of Nivalis Therapeutics, a publicly traded company acquired by Alpine Immune Sciences, in 2017 and Chief Financial Officer and Secretary from 2015 to 2017. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma Inc., a publicly traded company acquired by Pfizer Inc. Prior to this, he served as Chief Financial Officer of Sievers Instruments, Treasurer and Controller for the Waukesha division of Dover Corporation and Accountant with Coopers & Lybrand. Mr. Carruthers serves on the boards of Elevation Oncology (Nasdaq: ELEV) and OnKure, Inc., . Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

What is R. Michael Carruthers' net worth?: The estimated net worth of R. Michael Carruthers is at least $222,308.80 as of September 20th, 2024. Dr. Carruthers owns 6,904 shares of Edgewise Therapeutics stock worth more than $222,309 as of November 23rd. This net worth approximation does not reflect any other investments that Dr. Carruthers may own. Additionally, Dr. Carruthers receives an annual salary of $386,010.00 as CFO at Edgewise Therapeutics. Learn More about R. Michael Carruthers' net worth.
How old is R. Michael Carruthers?: Dr. Carruthers is currently 66 years old. There are 8 older executives and no younger executives at Edgewise Therapeutics. The oldest executive at Edgewise Therapeutics is Dr. Joanne M. Donovan M.D., Ph.D., Chief Medical Officer, who is 67 years old. Learn More on R. Michael Carruthers' age.
What is R. Michael Carruthers' salary?: As the CFO of Edgewise Therapeutics, Inc., Dr. Carruthers earns $386,010.00 per year. There are 4 executives that earn more than Dr. Carruthers. The highest earning executive at Edgewise Therapeutics is Dr. Kevin Koch Ph.D., President, CEO & Director, who commands a salary of $905,520.00 per year. Learn More on R. Michael Carruthers' salary.
How do I contact R. Michael Carruthers?: The corporate mailing address for Dr. Carruthers and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at [email protected]. Learn More on R. Michael Carruthers' contact information.
Has R. Michael Carruthers been buying or selling shares of Edgewise Therapeutics?: R. Michael Carruthers has not been actively trading shares of Edgewise Therapeutics during the last quarter. Most recently, R Michael Carruthers sold 125,092 shares of the business's stock in a transaction on Friday, September 20th. The shares were sold at an average price of $28.57, for a transaction totalling $3,573,878.44. Following the completion of the sale, the chief financial officer now directly owns 6,904 shares of the company's stock, valued at $197,247.28. Learn More on R. Michael Carruthers' trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, Edgewise Therapeutics insiders bought shares 2 times. They purchased a total of 465,402 shares worth more than $5,100,965.10. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 592,545 shares worth more than $11,865,014.27. The most recent insider tranaction occured on September, 23rd when General Counsel John R Moore sold 20,922 shares worth more than $578,074.86. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 9/23/2024.

R. Michael Carruthers Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/20/2024	Sell	125,092	$28.57	$3,573,878.44	6,904
5/2/2024	Sell	2,157	$18.91	$40,788.87	35,230
1/23/2024	Sell	90,000	$15.78	$1,420,200.00	29,024
5/2/2023	Sell	1,336	$8.90	$11,890.40	16,126

R. Michael Carruthers Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $32.20

$31.76

$32.72

50 Day Range

MA: $30.92

$16.86

$36.62

2 Week Range

Now: $32.20

$5.93

$38.12

Volume

352,873 shs

Average Volume

943,179 shs

Market Capitalization

$3.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

2024 Election Year Stocks: Uncover Hidden Gems!

From Darwin | Ad

Secure your copy now by clicking this link.

R. Michael Carruthers Biography and Net Worth

What is R. Michael Carruthers' net worth?

How old is R. Michael Carruthers?

What is R. Michael Carruthers' salary?

How do I contact R. Michael Carruthers?

Has R. Michael Carruthers been buying or selling shares of Edgewise Therapeutics?

Who are Edgewise Therapeutics' active insiders?

Are insiders buying or selling shares of Edgewise Therapeutics?